Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensituximab - Precision Biologics

Drug Profile

Ensituximab - Precision Biologics

Alternative Names: NEO-101; NEO-102; NPC-1C

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neogenix Oncology
  • Developer Duke University Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Johns Hopkins Medical Institutions; Montefiore Medical Center; National Cancer Institute (USA); Precision Biologics; University of North Carolina; University of Texas Southwestern Medical Center; Yale University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 19 Dec 2019 Precision Biologics terminates a phase I/II trial in Pancreatic Cancer in USA due to trial futility as per DSMB recommendation (NCT01834235)
  • 02 Aug 2019 Phase II development is ongoing in the US
  • 26 Feb 2018 Ligand Pharmaceuticals, prior to February 2018, acquires the economic rights to certain programmes based on Selexis owned SUREtechnology platform, including the ensituximab programme
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top